Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Novavax Inc (NVAX) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Novavax Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.73, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Novavax Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILNVAX
Sector
Leveraged / InverseHealth
52-Week High
$87.24$11.19
52-Week Low
$18.74$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $20.73, showing minimal daily movement with a 0.1% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $21 with support at $20. Recent corporate actions include a 1:2 stock split scheduled for May 28, 2026. Natural gas market volatility and weather-dependent demand continue to influence price movements.

The outlook remains cautious given bearish technical signals and natural gas market uncertainty. Investment opportunities exist for tactical traders during volatility spikes, but risks include weather-dependent demand fluctuations and production increases. The stock split may improve liquidity but doesn't alter fundamental valuation. Investors should monitor EIA storage reports and weather forecasts as key catalysts.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX